Medical Writer 2
Rezolute Bio
Medical Writer 2
Rezolute Bio
Develops monoclonal antibodies for rare diseases
Location: Redwood City, California
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Our antibody therapy, RZ358 (ersodetug), is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).
We are seeking an experienced and detail-oriented Medical Writer II to join our dynamic team. In this role, you will be responsible for developing high-quality, scientifically accurate, and regulatory-compliant documents for clinical trials, regulatory submissions and medical affairs. Interfaces with cross-functional groups to ensure accurate and timely completion/delivery of information and review of writing projects. You will collaborate with cross-functional teams, including clinical researchers, regulatory professionals, and subject matter experts, to produce materials that support the advancement of clinical trials, product development, and regulatory submissions.
The Medical Writer II serves as medical writing lead on assigned projects. Works closely with in-function and cross-functional team(s) on project strategies. Implements all activities related to the preparation of writing projects. Coordinates the review, approval, and other appropriate functions involved in the production of writing projects. Negotiates with functional areas on project outcomes and deliverables to meet conflicting demands. Identifies and proposes solutions to resolve issues and questions arising during the writing process, including resolution or elevation as appropriate. Arranges and conducts review meetings with the team. Ensures required documentation is obtained.
Skills & Competencies:
Rezolute (RZLT) currently anticipates the base salary for the Medical Writer II role could range from $110,000 to $135,000 and will depend, in part, on the successful candidate’s geographical location and their qualifications for the role, including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending, in part, on company and individual performance and at the Company’s discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications, education, experience and geographical location of the selected candidate. Rezolute offers competitive compensation, stock options and a rich benefits package.
Qualifying employees are eligible to participate in benefit programs such as:
We are an Equal Opportunity Employer and do not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.
Develops monoclonal antibodies for rare diseases
Rezolute Bio develops therapies for rare diseases, led by RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. RZ358 is a human monoclonal antibody that binds insulin to reduce its activity, aiming to lessen hypoglycemia, while RZ402 is an oral plasma kallikrein inhibitor for DME. The company differentiates itself by targeting rare, unmet-need conditions and pursuing late-stage candidates in both antibody and small-molecule formats. Its goal is to bring approved therapies to patients by advancing its programs through development to commercialization.
Explore more opportunities at Rezolute Bio